Zsuzsanna Helyes

Professor in pharmacology

Role in PharmNovo: Consultant and scientific advisor.

University/company: University of Pecs / PharmInVivo.

Resumé: Dr Helyes work in the fields of pain and inflammation and has great expertise in a variety of experimental models with special emphasis on in vivo studies. She also started PharmInVivo and today lead the company which is a spin-out company based in the Department of Pharmacology and Pharmacotherapy at the Medical Faculty & Szentagothai Research Center of the University of Pécs. The team focuses on animal models of chronic diseases and has a complete repertoire of nociceptive tests in both rats and mice.

Member of:

Pain

Latest news

View all

March 21, 2024

Positive final Phase I results

The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.

Meet Bengt von Mentzer, founder and Chief scientific advisor

March 10, 2024

Meet Bengt von Mentzer, founder and Chief scientific advisor

Bengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.

January 30, 2024

NIDA funds studies

The US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.

Meet Olof Breuer, MD, Clinical pharmacology lead

January 30, 2024

Meet Olof Breuer, MD, Clinical pharmacology lead

Olof Breuer's presence at PharmNovo exemplifies the company's commitment to pioneering advancements in pain relief. His visionary approach, honed through years of experience, positions him as a driving force in the quest for novel concepts in neuropathic pain relief.